Understand the EBITDA multiples, value drivers, and deal structures that determine acquisition pricing for DOT-compliant collection networks, MRO services, and employer drug screening programs in today's lower middle market.
Find Drug Testing Services Businesses For SaleDrug testing service businesses are typically valued on a multiple of Seller's Discretionary Earnings or EBITDA, with buyers placing the highest premiums on recurring employer contract revenue, DOT consortium management, and diversified client rosters with no single account exceeding 20% of volume. Because many operators commingle pass-through laboratory and MRO charges with true service revenue, buyers normalize financials carefully to isolate collection fees and value-added margin before applying a multiple. In a consolidating market where national occupational health platforms actively acquire regional networks, well-prepared businesses with clean compliance records and documented contracts are commanding multiples at the higher end of the 3.5x–6.0x range.
3.5×
Low EBITDA Multiple
4.75×
Mid EBITDA Multiple
6×
High EBITDA Multiple
Businesses at the low end of the range typically show heavy client concentration in one or two employer accounts, rely on the owner for MRO reviews or key account relationships, or carry unresolved DOT or SAMHSA compliance gaps. Mid-range multiples apply to stable collection networks with diversified employer bases, current certifications, and documented contracts but limited technology infrastructure or scalability. Premium multiples of 5.5x–6.0x are reserved for businesses with multi-year employer contracts across transportation, construction, and healthcare sectors, proprietary mobile collection fleets, electronic chain-of-custody systems, and clean five-year regulatory histories that are immediately attractive to PE-backed roll-up platforms or national occupational health acquirers.
$2,800,000
Revenue
$620,000
EBITDA
4.8x
Multiple
$2,976,000
Price
SBA 7(a) loan financing covering approximately 75% of the purchase price ($2,232,000) at a 10-year term, 12% buyer equity injection ($297,600), seller note of $297,600 held for 24 months subordinated to SBA lender, and a performance earnout of up to $150,000 tied to retention of the top five employer accounts generating 40% of collections revenue through the 18 months following close. Deal structured as an asset purchase with allocated consideration across employer client contracts, DOT consortium agreements, collection site equipment, and goodwill, with a 24-month non-compete and 6-month paid transition period for the seller.
EBITDA Multiple
The most widely used method for drug testing service acquisitions. Buyers calculate normalized EBITDA by removing pass-through lab and MRO costs from gross revenue, adding back owner compensation above market-rate replacement salary, and adjusting for any one-time expenses. The resulting figure is multiplied by a range of 3.5x–6.0x depending on client diversification, contract quality, regulatory compliance, and technology infrastructure.
Best for: Established businesses with $500K or more in EBITDA and a documented recurring employer client base, particularly those targeting PE-backed strategic buyers or SBA-financed acquisitions.
Seller's Discretionary Earnings (SDE) Multiple
Applied to owner-operated collection businesses where the owner is active in daily operations, MRO coordination, or direct account management. SDE adds back the owner's full compensation and personal benefits to pre-tax earnings. Multiples typically range from 2.5x–4.0x SDE for businesses under $1M in adjusted earnings, reflecting the transition risk and owner dependency inherent in many independent drug testing operations.
Best for: Small single-operator or family-run collection sites and DOT consortium programs generating under $500K in annual earnings where the owner is central to client retention and compliance oversight.
Revenue Multiple
Less common but occasionally used as a sanity check or for businesses with strong top-line revenue but compressed margins due to high pass-through lab costs. Buyers typically apply 0.5x–1.0x of true service revenue, explicitly excluding pass-through laboratory and specimen handling charges that carry minimal margin. This method is most useful when evaluating acquisition targets within a roll-up platform that can immediately reduce lab costs through volume purchasing agreements.
Best for: Strategic acquirers with existing lab contracts and purchasing leverage who are acquiring a collection network primarily for its employer client relationships and geographic footprint rather than current profitability.
Diversified Employer Contract Base Across Regulated Industries
A client roster spread across transportation, construction, healthcare, and government sectors — with no single employer account exceeding 20% of collections volume — significantly reduces churn risk and supports premium multiples. Multi-year written contracts with defined testing volume commitments are far more valuable than informal purchase-order relationships, particularly for DOT-regulated employers who face non-discretionary federal testing mandates.
DOT Consortium Management and MRO Services
Operating as a designated employer representative managing DOT random testing consortiums or providing in-house Medical Review Officer services creates high switching costs and subscription-like recurring revenue. Buyers place substantial value on these services because they lock in employer clients across annual program cycles and generate margin well above standard specimen collection fees.
Proprietary Collection Site Network or Mobile Fleet
Owning or operating a network of dedicated collection sites, or a mobile collection fleet serving worksites in transportation and construction, creates a durable competitive barrier that national competitors cannot replicate quickly. Geographic coverage density in underserved markets or exclusive facility agreements with occupational health clinics are particularly attractive to acquirers building regional platforms.
Clean Five-Year Regulatory Compliance Record
An unblemished history with no DOT audit findings, SAMHSA violations, chain-of-custody discrepancies, or HIPAA citations dramatically reduces buyer due diligence risk and supports higher multiples. Buyers and their lenders — especially SBA lenders — will scrutinize compliance records thoroughly, and a single unresolved citation can trigger price reductions, escrow holdbacks, or deal termination.
Electronic Chain-of-Custody and HR System Integration
Businesses operating with a modern Laboratory Information Management System (LIMS), electronic chain-of-custody software, and integrations into employer HR or payroll platforms command technology premiums from strategic buyers. These capabilities reduce manual processing costs, improve result turnaround times, and signal scalability to acquirers looking to integrate the business into a broader occupational health platform without significant IT investment.
Heavy Revenue Concentration in One or Two Employer Accounts
When a single employer client represents more than 20–25% of total collections volume or revenue, buyers discount the acquisition price substantially or demand earnout provisions tied to that account's post-close retention. Transportation and construction companies frequently represent outsized concentration for independent operators, and the loss of one contract post-acquisition can impair the business's ability to service SBA debt, making lenders particularly cautious.
Unresolved DOT, SAMHSA, or State Compliance Violations
Expired collector certifications, open DOT audit findings, chain-of-custody documentation gaps, or unresolved SAMHSA citations are deal-killers or severe value-reducers. Buyers conducting due diligence will request five years of regulatory correspondence, and any evidence of systemic non-compliance will prompt either a significant price reduction or outright withdrawal. Sellers should resolve all open compliance issues before engaging the market.
Undocumented Client Relationships Based on Owner's Personal Network
Informal employer relationships managed entirely through the owner's personal contacts — with no written contracts, service agreements, or documented pricing — create severe transition risk that buyers and SBA lenders cannot underwrite confidently. When the value of the business walks out the door with the seller, buyers will either require a prolonged earnout, a minority equity rollover, or will decline to proceed at full price.
Pass-Through Revenue Inflating Apparent Top-Line Without Real Margin
Many drug testing operators report gross revenues that include 100% of laboratory and specimen analysis fees passed through to clients, creating the appearance of a larger business than the underlying economics support. Buyers normalize financials by stripping these pass-throughs to isolate true collection and MRO service margin. Sellers who conflate pass-through billings with earned revenue will face frustrating valuation disconnects during negotiations.
Outdated Paper-Based Processes and Lack of Digital Reporting
Collection businesses still operating with paper chain-of-custody forms, manual result transcription, and phone-based employer reporting are viewed as operationally fragile and expensive to integrate. In a market where competitors offer real-time electronic result delivery and employer portal access, paper-dependent operations face both client attrition risk and significant technology upgrade costs that buyers will deduct from any offered price.
Find Drug Testing Services Businesses For Sale
Signal-scored targets with seller motivation, multiples, and outreach — free to join.
Most drug testing service businesses in the $1M–$5M revenue range sell for 3.5x–6.0x normalized EBITDA, depending on client diversification, contract quality, regulatory compliance history, and technology infrastructure. A well-run DOT consortium management operation with multi-year employer contracts, electronic chain-of-custody systems, and no compliance violations can realistically achieve the 5.0x–6.0x range. Businesses with heavy client concentration, owner dependency, or paper-based processes typically land between 3.5x and 4.5x.
Sophisticated buyers — and their SBA lenders — will always strip pass-through laboratory and specimen handling charges from reported revenue before applying a valuation multiple. These pass-throughs may represent 40–60% of gross billings but carry minimal or no true margin for the collection operator. Sellers should proactively prepare restated financials that isolate collection fees, MRO service revenue, and DOT program management fees from pure lab pass-throughs to avoid valuation disputes and accelerate due diligence.
Yes. Drug testing service businesses are generally SBA 7(a) eligible as established B2B service operations with tangible client contracts and identifiable assets. Most acquisitions in the $1.5M–$5M price range use SBA 7(a) financing with a 10–15% buyer equity injection, a 10-year loan term, and a seller note of 5–10% held for 24 months as required by SBA lender standby provisions. Lenders will pay close attention to client concentration risk, regulatory compliance history, and the seller's transition plan when underwriting the deal.
Private equity roll-up platforms targeting occupational health, background screening, or workforce compliance are attracted to drug testing businesses because the revenue is anchored by non-discretionary federal DOT mandates rather than discretionary employer spending. Businesses with DOT consortium management, MRO services, and multi-site collection networks offer immediate geographic expansion and recurring revenue streams that are difficult to build organically. Clean compliance records and electronic chain-of-custody technology reduce integration costs and allow platforms to onboard acquisitions quickly.
Most owner-operators should plan for a 12–18 month exit process from initial preparation through closing. The front-end preparation — organizing three years of financial statements, documenting client contracts, ensuring all collector certifications and DOT authorizations are current, and resolving any open compliance issues — typically takes 3–6 months before the business is ready to market. Active marketing, buyer qualification, due diligence, and SBA loan processing generally add another 6–12 months. Sellers who begin preparation early and engage an experienced healthcare-focused M&A advisor consistently achieve better pricing and smoother closings.
Client concentration and owner dependency are consistently the top two concerns for buyers and SBA lenders evaluating drug testing acquisitions. When a single transportation company or construction employer represents more than 20% of collections volume, or when the seller personally manages MRO reviews and key account relationships with no staff backup, buyers view the business as high-risk post-close. Sellers who cross-train staff, formalize client contracts, and reduce personal involvement in account management before going to market will see materially better valuations and fewer earnout demands.
The overwhelming majority of lower middle market drug testing acquisitions are structured as asset purchases rather than stock sales. Asset purchases allow buyers to step up the tax basis of acquired assets — particularly goodwill and client contracts — and avoid inheriting historical liabilities including any undisclosed regulatory violations, employment claims, or vendor disputes. Sellers typically prefer stock sales for the capital gains tax treatment, but buyers and SBA lenders almost universally require asset purchase structures. A qualified M&A attorney with healthcare transaction experience can help sellers negotiate asset allocation schedules that minimize tax impact within an asset purchase framework.
More Drug Testing Services Guides
DealFlow OS surfaces acquisition targets, scores seller motivation, and generates outreach — free to join.
Start finding deals — freeNo credit card required
For Buyers
For Sellers